Bio-Path shares made an incredible run on Wednesday after the company announced interim results from its mid-stage leukemia trial.
Synthetic biology company Twist Bioscience expects to price 5 million shares for an initial public offering valued up to more than $103 million.
Bluebird Bio saw its shares dip on Wednesday after the firm announced the pricing of a secondary offering of more than 3 million shares.
PDL BioPharma, Inc. (NASDAQ: PDLI) appears to have a new royalty stream coming its way.  The company announced this morning that it is now set to start receiving royalty payments from Roche’s...
Solid Biosciences shares more than doubled on Thursday after the company announced a key update from the FDA.
CV Therapeutics, Inc. (NASDAQ: CVTX) is seeing a surge in its shares this morning.  It looks like CV is the next biotech merger target now that Astellas Pharma Inc. submitted a $16.00 buyout offer...
Sterling Bancshares Inc. (NASDAQ: SBIB) has just filed with the SEC to sell up to $150 million in a mixed securities shelf filing.  The bank listed that it will sell any combination of preferred...
What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of shareholder value? That's what happened to Bio-Path.
Solid Bio shares were absolutely crushed on Thursday after preliminary data from the firm’s midstage trial in Duchenne muscular dystrophy was not up to par.
Goldman Sachs has maintained coverage of 2seventy bio with a Buy recommendation.
Source: ThinkstockBiotech and emerging health care technology companies both fit into a high-stake poker match on Wall Street. Investors can earn exponential rewards if they are right, or they can...
Eleven Biotherapeutics was at the top of the list for gainers in the market Wednesday. This move comes on an update from the company’s most advanced study.
The massive data breach at credit reporting agency Equifax could have a major impact on your ability to get a mortgage. Here are some steps to take to battle the potential damage.
iBio has provided an update on its COVID-19 vaccine manufacturing capacity and said that it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals.
Bradley Louis Radoff reported acquiring 6 million shares of Sesen Bio.